Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amphastar PharmaceuticalsAMPH -0.58%82 Debt-to-Equity is 0.89 as of Mar. 2026, which is 394% above its 10-year median of 0.18. GuruFocus rates AMPH with a GF Score™ of 82/100 and a GF Value™ of $48.94 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 812 Drug Manufacturers companies, Amphastar Pharmaceuticals ranks worse than 83.62% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Amphastar Pharmaceuticals's Debt-to-Equity or its related term are showing as below:
AMPH'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.11 Med: 0.18 Max: 1.13
Current: 0.89
During the past 13 years, the highest Debt-to-Equity Ratio of Amphastar Pharmaceuticals was 1.13. The lowest was 0.11. And the median was 0.18.
AMPH's Debt-to-Equity is ranked worse than 83.62% of 812
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs AMPH: 0.89
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Amphastar Pharmaceuticals Debt-to-Equity Related Terms
Amphastar Pharmaceuticals Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AMPH vs ETON, PCRX, BIOA: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amphastar Pharmaceuticals Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Amphastar Pharmaceuticals's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amphastar Pharmaceuticals (AMPH) has a Debt-to-Equity of 0.89 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Amphastar Pharmaceuticals and its competitors. This is 394% above median its historical median of 0.18. Over the past decade, Amphastar Pharmaceuticals' Debt-to-Equity has ranged from 0.11 to 1.13. According to the industry distribution chart, Amphastar Pharmaceuticals ranks #679 out of 812 companies in the Drug Manufacturers industry, placing it in the top 83.6%.
Is Amphastar Pharmaceuticals' Debt-to-Equity too high?
Amphastar Pharmaceuticals' current Debt-to-Equity of 0.89 is 394% above median its 10-year median of 0.18. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 1.13. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Amphastar Pharmaceuticals' value of 0.89 is 229.6% above this industry median. Based on the distribution chart, Amphastar Pharmaceuticals ranks #679 out of 812 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Amphastar Pharmaceuticals has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amphastar Pharmaceuticals' Debt-to-Equity compare to ETON and PCRX?
According to the Drug Manufacturers industry distribution chart, Amphastar Pharmaceuticals ranks #679 out of 812 companies for Debt-to-Equity. This places Amphastar Pharmaceuticals in the lower half of its industry. The industry median Debt-to-Equity is 0.27. Amphastar Pharmaceuticals' value of 0.89 is 229.6% above this benchmark. Historically, Amphastar Pharmaceuticals' own Debt-to-Equity has ranged from 0.11 to 1.13 over the past decade. While the company's 10-year median is 0.18 vs. the industry median of 0.27, Amphastar Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amphastar Pharmaceuticals's current Debt-to-Equity of 0.89 is 229.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Amphastar Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amphastar Pharmaceuticals's current Debt-to-Equity is 0.89, which is 394% above median its own 10-year median of 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amphastar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals (AMPH) is currently considered Significantly Undervalued. The stock's GF Value™ is $48.94, compared to a current price of $19.75 — trading 59.7% below its estimated fair value. The current Debt-to-Equity is 0.89, which is 394% above median its 10-year median of 0.18 and 229.6% above the Drug Manufacturers industry median of 0.27. Amphastar Pharmaceuticals' overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Amphastar Pharmaceuticals (AMPH), the current Debt-to-Equity is 0.89 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amphastar Pharmaceuticals (AMPH) Overvalued in 2026?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued.
The current stock price of $19.75 is trading 59.7% below its estimated GF Value™ of $48.94.
GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for AMPH:
Debt-to-Equity: 0.89 (394% above median its 10-year median of 0.18)
GF Value™: $48.94 vs. price of $19.75 (59.7% below fair value)
Industry Position: 229.6% above the Drug Manufacturers median (#679 of 812)
No single metric tells the full story. See the AMPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
82GF Score
Get the complete analysis for AMPH
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMPH has been successfully added to your 
